Toxicity and outcome results of RTOG 9311: A phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non–small-cell lung carcinoma

To evaluate prospectively the acute and late morbidities from a multiinstitutional three-dimensional radiotherapy dose-escalation study for inoperable non-small-cell lung cancer.A total of 179 patients were enrolled in a Phase I-II three-dimensional radiotherapy dose-escalation trial. Of the 179 patients, 177 were eligible. The use of concurrent chemotherapy was not allowed. Twenty-five patients received neoadjuvant chemotherapy. Patients were...